In behavioral experiments, REPOPS boosted locomotor activity and reduced depression-like behaviors. Importantly, the treatment did not merely produce short-term excitation; it triggered lasting state changes reminiscent of ECT-like outcomes. These functional effects were accompanied by a striking cellular transformation: adult neurons entered a dematuration program, adopting gene expression signatures similar to early postnatal development.

Timing proved critical. Stimulation for three days yielded only transient transcriptional changes, whereas ten-day stimulation produced a stable dematuration state that persisted for more than a month. Genome-wide chromatin accessibility mapping further supported permanence, revealing widespread, durable remodeling of regulatory landscapes that can outlast the stimulation window.

The most surprising clue came from cell-cycle-linked molecular readouts. Although neurons are post-mitotic, REPOPS induced expression patterns characteristic of the G2/M phase in dividing cells, along with mitosis-associated nuclear hallmarks. These included histone phosphorylation, nuclear lamina disruption, and chromatin condensation—signatures consistent with nuclear reprogramming rather than transient activation.

To test causality, the team used genome editing to remove Cyclin B, a central G2/M transition regulator. Without Cyclin B, both nuclear reprogramming and stimulation-driven behavioral changes were reduced, implicating a mechanistic driver that connects “cell-cycle-like” signaling to the redefined neuronal identity.

The study then addressed how reprogramming altered computation. Using calcium imaging in behaving animals, the researchers observed a non-binary effect: REPOPS shifted information encoding in a patterned way. Spatial coding was suppressed, while speed-related coding was enhanced, and this altered coding strategy lasted for over two weeks.

Together, molecular, nuclear, epigenomic, and systems-level results support a model in which ECT-like stimulation creates an “intermediate state” of heightened plasticity. In this framework, neurons reside neither in a fully mature nor fully immature attractor state. Instead, the precise configuration may depend on stimulation strength, frequency, and context—factors that could be beneficial in depression but harmful under conditions such as epilepsy or neurodegeneration.

Finally, clinical relevance was suggested by reanalyzing postmortem RNA-seq datasets from mood-disorder patients. Dentate gyrus neurons from ECT-treated individuals showed an immature-like expression pattern similar to that observed in stimulated animals, strengthening the case that dematuration-like processes may occur in humans.

Subject of Research: Animals
Article Title: Repetitive Neuronal Activation Regulates Cellular Maturation State via Nuclear Reprogramming
News Publication Date: 17-Jul-2026
Web References: http://dx.doi.org/10.1038/s41467-026-74202-w
References: Nature Communications (DOI: 10.1038/s41467-026-74202-w)
Image Credits: Tomoyuki Murano

Keywords: electroconvulsive therapy; rTMS; neuronal stimulation; nuclear reprogramming; dematuration; chromatin accessibility; cell-cycle genes; Cyclin B; neuronal plasticity

This comprehensive study aggregates data from randomized controlled trials (RCTs) conducted over nearly four decades, reflecting the breadth of research spanning from 1985 through 2024. The researchers embarked on an ambitious quest, meticulously scouring six English and four Chinese academic databases to identify trials that evaluated the effects of neuroregulatory interventions on patients diagnosed with psychiatric disorders, confirmed by internationally recognized diagnostic systems including the ICD-11 and DSM-5. The inclusion criterion centered on studies that applied neuromodulation techniques explicitly aiming to regulate not just psychiatric symptoms but also body weight parameters.

From this extensive literature search, ten eligible RCTs were identified, collectively involving 528 patients diagnosed with a spectrum of psychiatric conditions including eating disorders, schizophrenia, and major depressive disorder. This diverse patient population allowed for a multifaceted examination of neuroregulatory interventions across different diagnostic categories. The meta-analysis primarily focused on quantifiable outcomes related to BMI and body weight, employing Hedges’ g as the standardized effect size metric to enable robust comparisons across heterogeneous study designs.

Crucially, the analysis revealed substantial heterogeneity among the included studies, as evidenced by I² statistics exceeding 70% for both BMI and body weight outcomes. Such high heterogeneity underscores the variability in study populations, intervention modalities, and measurement techniques, which collectively complicate the extraction of definitive conclusions. Despite this variability, the pooled effect sizes did not demonstrate statistically significant reductions in BMI or body weight attributable to neuroregulatory interventions, challenging prior assumptions about the potential dual benefits of these therapies.

The absence of significant impact on weight parameters highlights an intriguing dissociation between the neurological modulation of psychiatric symptoms and metabolic regulation. While neuromodulation techniques like TMS have been shown to influence neural circuits implicated in mood and cognition, their capacity to effect systemic physiological changes such as weight modulation appears limited, at least within the parameters and study durations analyzed. This invites further exploration into the neurobiological mechanisms underlying weight regulation in mentally ill populations and whether these mechanisms can be targeted more effectively.

Moreover, the meta-analysis underscores the methodological challenges inherent in studying complex interactions between neuropsychiatric interventions and somatic outcomes. Variations in trial duration, intensity and frequency of neuromodulation sessions, and adjunct pharmacotherapies may all impact outcomes. The studies included showed considerable diversity in these factors, which likely contributed to inconsistent findings and the observed heterogeneity. Future research might benefit from standardized protocols and longer follow-up to fully elucidate any delayed or cumulative effects on weight.

Importantly, the study authors advocate for caution in interpreting current findings as conclusive. The limited number of high-quality RCTs, combined with relatively small sample sizes and short follow-up periods, restricts the statistical power necessary to detect subtle or long-term impacts on body weight. As such, neuroregulatory interventions cannot yet be recommended as viable strategies for weight management in psychiatric populations, a domain where metabolic side effects of psychotropic medications often pose significant health risks.

This meta-analysis also invites reflection on the broader clinical implications. Psychiatric patients frequently experience weight gain due to medication side effects, lifestyle factors, and the pathophysiology of mental illness itself. While neuroregulatory techniques may offer symptom relief, addressing metabolic health remains a critical unmet need. Integrative treatment models that combine neuropsychiatric care with targeted metabolic interventions might prove more effective in improving overall patient outcomes.

Technologically, the field of neuromodulation continues to advance rapidly, with emerging modalities such as transcranial direct current stimulation (tDCS) and non-invasive vagus nerve stimulation showing promise. Future trials incorporating these novel techniques may provide richer insights into the potential for modulating neural circuits governing appetite, metabolism, and energy expenditure. Additionally, leveraging neuroimaging and biomarker studies could help identify patient subgroups more likely to benefit from combined neuroregulatory and metabolic interventions.

In summary, this meta-analysis provides a critical appraisal of the current evidence base surrounding the impact of neuroregulatory interventions on weight in patients with mental illness. Despite the theoretical appeal and clinical hope vested in these technologies, the findings indicate that, as of now, they do not produce significant changes in BMI or body weight. This highlights an urgent need for more rigorous, large-scale RCTs with extended follow-up periods to unravel the complex interplay between brain modulation and metabolic regulation.

The study serves as a clarion call for the scientific community to deepen investigations into integrative treatment strategies that address both the neuropsychiatric and metabolic dimensions of mental illness. Future research should emphasize methodological rigor, including standardized intervention protocols, comprehensive metabolic assessments, and the inclusion of diverse patient populations to ensure findings are broadly applicable.

As mental health care evolves towards precision medicine, understanding the nuanced effects of interventions on both brain function and systemic health will be essential. While neuroregulatory interventions have transformed aspects of psychiatric treatment, their role in managing weight remains unsubstantiated, marking an important frontier for future scientific inquiry.

This emerging knowledge not only guides clinicians in setting realistic expectations for neuromodulation therapies but also informs patients and caregivers about the current scope and limitations of these interventions. Ultimately, advancing this line of research promises to optimize therapeutic outcomes and enhance quality of life for individuals living with mental illness.

Subject of Research: The effectiveness of neuroregulatory interventions on weight management in patients with mental illness.

Article Title: Impact of neuroregulatory interventions upon weight in patients with mental illness: a meta-analysis of randomised controlled trials.

Article References:
Ren, W., Zhu, Y., Yang, R. et al. Impact of neuroregulatory interventions upon weight in patients with mental illness: a meta-analysis of randomised controlled trials.
BMC Psychiatry 25, 864 (2025). https://doi.org/10.1186/s12888-025-07328-8

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07328-8